POLESTAR Trial - An International Multi-center Early Discharge TAVI Program

NCT ID: NCT03910751

Last Updated: 2025-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

252 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-01

Study Completion Date

2024-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An international multi-center prospective observational study to address safety and feasibility of an early discharge protocol in patients with symptomatic severe aortic stenosis who are eligible for transfemoral TAVI with the Boston Scientific ACURATE Neo Aortic Bioprosthesis transcatheter heart valve.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this International multi-center prospective observational study, 250 patients with severe symptomatic aortic stenosis (AS) and eligibility for transfemoral TAVI with ACURATE Neo Bioprosthesis, will be pre-procedurally selected for participation in an early discharge protocol in which patients are discharged within 48 hours after uncomplicated TAVI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis

Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eligible for ACURATE Neo valve implantation
* Patient agrees to follow-up duration
* Patient is able to understand and sign written informed consent

Exclusion Criteria

* BMI \> 35
* Pregnancy

Cardiac

* Moderate to severely impaired left ventricular ejection fraction (LVEF \<35%)
* Mitral regurgitation \> moderate
* Pulmonary hypertension (sPAP \> 60mmHg)
* No complex coronary artery disease
* Untreated high degree AV-block or RBBB

Pulmonary

* COPD Gold \> 2

Kidney function

* GFR \< 35ml/min

Frailty

* Inappropriate social support and/or (familial) care
* Patient is walking aid dependent

TAVI strategy

* Presence of severe peripheral artery disease
* Transfemoral approach not possible

Follow up

* Inability to adhere to follow-up
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role collaborator

Erasmus Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nicolas van Mieghem

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicolas Van Mieghem, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ASZ Aalst

Aalst, , Belgium

Site Status

AZ Sint-Jan Brugge

Bruges, , Belgium

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

AZ Maria Middelares

Ghent, , Belgium

Site Status

Royal Columbian Hospital

New Westminster, , Canada

Site Status

Sunnybrook Health Sciences Centre

Toronto, , Canada

Site Status

Vancouver General Hospital

Vancouver, , Canada

Site Status

University Medical Center Groningen

Groningen, , Netherlands

Site Status

Leiden University Medical Center

Leiden, , Netherlands

Site Status

St. Antonius Hospital

Nieuwegein, , Netherlands

Site Status

Erasmus University Medical Center

Rotterdam, , Netherlands

Site Status

Utrecht University Medical Center

Utrecht, , Netherlands

Site Status

University Hospital Sussex NHS Foundation Trust

Brighton, , United Kingdom

Site Status

Leeds Teaching Hospitals NHS Trust

Leeds, , United Kingdom

Site Status

University Hospitals of Leicester NHS Trust

Leicester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Canada Netherlands United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

POLESTAR_EMC2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.